New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
08:31 EDTNKTRNektar announces initiation of Phase 2 study of etirinotecan pegol
Nektar announced the start of a Phase 2 investigator-initiated study of etirinotecan pegol in patients with metastatic and recurrent NSCLC. The primary endpoint of the Phase 2 study is overall response rate. Secondary endpoints include progression free survival, overall survival, median duration of response and the safety profile of etirinotecan pegol in patients with NSCLC after failure of second-line therapy. The open label, single-arm trial is expected to enroll approximately 37 patients who will receive etirinotecan pegol once every three weeks as monotherapy.
News For NKTR From The Last 14 Days
Check below for free stories on NKTR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2014
09:07 EDTNKTRNektar reports positive preclinical data for two oncology programs
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use